The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)
2024 · JTO Clinical and Research Reports · 13 citations
https://doi.org/10.1016/j.jtocrr.2024.100720